Intercell AG

euro adhoc: Intercell AG
Board of Directors (Appointments and Changes) / Intercell appoints Management Board for further growth - Gerd Zettlmeissl - new CEO, Alexander von Gabain - new CSO, Werner Lanthaler - CFO

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Intercell AG (VSE, "ICLL") today announced that the company's Supervisory Board has appointed its management board with new responsibilities for the next three years. This appointment guarantees the optimal use of individual strength, know how and industrial experience of its members for the next stage of the company’s growth. The commercialization of Intercell’s own products, the successful partnering of its outstanding technologies and ongoing progress in its scientific and development work are now crucial for the further growth and strategic positing of the company with in the vaccine industry. The members of the new management board are Gerd Zettlmeissl (Chief Executive Officer), Alexander von Gabain (Chief Scientific Officer) and Werner Lanthaler (Chief Financial Officer).

"I am impressed by the achievements of Alexander von Gabain and his team. They managed to build up a world wide acknowledged vaccine company with late stage products and outstanding technologies in less than seven years. Under the new leadership of Gerd Zettlmeissl the company is now optimally prepared to master its upcoming challenges and periods of future growth", states Ernst Guenther Afting, Chairman of Intercell’s Supervisory Board.

Alexander von Gabain states: "The new definition of roles within our excellent team will enable us to use our individual strengths even better. As the company moves further downstream it was my own desire to free up again more time for our breakthrough technologies and our Business Development activities and thereby serve the future of Intercell in the very best fashion."

Gerd Zettlmeissl states: "It is a great honor to lead the company now as CEO. I take over a vaccine company with clinical programs, technologies and an organization, which are all in best shape. This will enable to create even more value for Intercell in the future."

Before joining Intercell as Chief Operating Officer in 2001 the future Chief Executive Officer, Gerd Zettlmeissl, served as CEO of Chiron’s fully integrated German vaccine subsidiary Chiron Behring. Having worked in the pharmaceutical industry for more than 20 years, Gerd Zettlmeissl has considerable experience in the discovery, development, manufacturing and commercialization of biotech products like e.g. novel vaccines against influenza and meningococcal infections.

Intercell’s founding CEO, Alexander von Gabain, will commit himself in his new position as Chief Scientific Officer to the company’s research and to creating new business from Intercell’s outstanding R&D and technology platforms. Before founding Intercell, Alexander von Gabain served as Chairman of the Department of Microbiology and Genetics at the University of Vienna and as Professor at the Karolinska Institute, Stockholm, Sweden.

Chief Financial Officer, Werner Lanthaler, will assume additional responsibilities for Intercell’s Marketing and Sales Activities to ensure a successful global launch of the company’s Japanese Encephalitis vaccine planned for 2007.  Before joining Intercell in 2001, Werner Lanthaler was Head of Marketing and Communication of the Austrian Federation of Industry and Senior Consultant at McKinsey & Company.

Michael Buschle will no longer be part of the Management Board of Intercell AG. He will continue his responsibility as General Manager of Intercell´s manufacturing subsidiary in Livingston, Scotland.

About Intercell  Intercell AG is a fast growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unaddressed medical need. The Company’s unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell’s technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis undergoing Phase III clinical trials, a vaccine for Hepatitis C in Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

@@start.t2@@end of announcement                                                 euro adhoc 24.10.2005 08:29:43

ots Originaltext: Intercell AG
Im Internet recherchierbar:

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN:      AT0000612601
Börsen:  Wiener Börse AG / official market

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: